Glucose Viaflo Baxter

Glucose Viaflo Baxter is an intravenous solution containing the active ingredient glucose monohydrate. It is supplied as a sterile liquid for infusion, marketed in the European Union and prescribed by healthcare professionals. The product provides a source of carbohydrate energy and helps maintain plasma osmolarity during medical treatment.

Glucose Viaflo Baxter is used in clinical settings where rapid carbohydrate supplementation or fluid balance is required. It is commonly administered under medical supervision for the following purposes:

- Treatment of hypoglycemia when oral glucose is not feasible - Fluid and electrolyte replacement in dehydration - Energy substrate during perioperative care - Support for patients receiving parenteral nutrition - Management of metabolic needs in critical care settings

Glucose Viaflo Baxter may be associated with a range of adverse reactions. Most are mild and transient, while some require immediate medical attention.

Common: - Local irritation at the infusion site - Mild hyperglycemia - Nausea or vomiting - Headache - Transient increase in serum osmolality

Serious: - Severe hyperglycemia leading to ketoacidosis - Allergic reaction or anaphylaxis - Fluid overload causing pulmonary edema - Electrolyte imbalance (e.g., hyponatremia) - Severe hypotension due to rapid infusion

When using Glucose Viaflo Baxter, clinicians should consider several safety measures to minimize risk. Important precautions include:

- Assess blood glucose levels before and during infusion - Adjust infusion rate in patients with cardiac or renal impairment - Monitor for signs of fluid overload, especially in elderly or compromised patients - Use aseptic technique to prevent infection at the infusion site - Review patient history for hypersensitivity to glucose solutions - Avoid rapid bolus administration unless specifically indicated

Glucose Viaflo Baxter can interact with other medications or clinical conditions. Awareness of these interactions helps ensure safe administration.

Avoid: - Concurrent use of high-dose insulin without glucose monitoring - Co-administration with hyperosmolar agents that may exacerbate fluid shifts

Use with caution: - Diabetic patients receiving oral hypoglycemics - Patients on loop diuretics or thiazide diuretics affecting electrolyte balance - Medications that alter renal function (e.g., NSAIDs, ACE inhibitors) - Drugs that may cause hypovolemia or dehydration - Agents that influence serum osmolality (e.g., mannitol)